Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Iovance Biotherapeutics Inc (IOVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,215,688
  • Shares Outstanding, K 123,169
  • Annual Sales, $ 0 K
  • Annual Income, $ -92,060 K
  • 36-Month Beta 1.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.27
  • Number of Estimates 5
  • High Estimate -0.22
  • Low Estimate -0.31
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.26 +18.77%
on 01/24/19
10.54 -6.93%
on 02/19/19
+1.03 (+11.73%)
since 01/22/19
3-Month
7.26 +35.12%
on 12/21/18
11.07 -11.38%
on 12/04/18
+0.79 (+8.76%)
since 11/21/18
52-Week
7.26 +35.12%
on 12/21/18
19.90 -50.70%
on 03/13/18
-8.69 (-46.97%)
since 02/22/18

Most Recent Stories

More News
Iovance Biotherapeutics to Host Fourth Quarter and Year-End 2018 Financial Results Conference Call and Webcast on Wednesday, February 27, 2019

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report...

IOVA : 9.81 (-0.61%)
Iovance Biotherapeutics to Present at Upcoming Investor and Medical Conferences

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company will...

IOVA : 9.81 (-0.61%)
Iovance Biotherapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company will...

IOVA : 9.81 (-0.61%)
JPM : 105.00 (-0.45%)
Iovance Biotherapeutics to Participate at November Investor Conferences

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management...

IOVA : 9.81 (-0.61%)
Iovance Biotherapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Company to Host Conference Call at 4:30pm ET Today

IOVA : 9.81 (-0.61%)
Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer's 33rd Annual Meeting

-- 38% Objective Response Rate (ORR) demonstrated in 47 Metastatic Melanoma patients who were unsuccessfully treated with a prior PD-1 blocking antibody

IOVA : 9.81 (-0.61%)
Iovance Biotherapeutics to Host Melanoma Program Update Event for Analysts and Investors During SITC 2018

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will host...

IOVA : 9.81 (-0.61%)
How This Underfollowed $6 Biotech Could Be Worth $10

The emerging cell therapy company Orgenesis Inc (ORGS) continues to prove they've got the right stuff, growing their revenue 50% in fiscal Q3 over the previous quarter and 143% compared to the previous...

IOVA : 9.81 (-0.61%)
ORGS : 5.20 (unch)
Iovance Biotherapeutics, Inc. Announces Closing of $252 Million Common Stock Public Offering

Offering Includes Exercise in Full of the Underwriter's Option to Purchase an Additional 3.3 Million Shares of Common Stock

IOVA : 9.81 (-0.61%)
Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update

- Company to Host Conference Call at 4:30pm ET Today -

IOVA : 9.81 (-0.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade IOVA with:

Business Summary

Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies...

See More

Key Turning Points

2nd Resistance Point 10.18
1st Resistance Point 10.00
Last Price 9.81
1st Support Level 9.66
2nd Support Level 9.50

See More

52-Week High 19.90
Fibonacci 61.8% 15.07
Fibonacci 50% 13.58
Fibonacci 38.2% 12.09
Last Price 9.81
52-Week Low 7.26

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar